

RESEARCH ARTICLE

Open Access

Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols

Manju Panghal^{1†}, Vivek Kaushal^{2†}, Sangeeta Kadayan^{1†} and Jaya Parkash Yadav^{1*†}

Abstract

Background: Over the past decade, advances in cancer treatments have been counterbalanced by a rising number of immunosuppressed patients with a multitude of new risk factors for infection. Hence, the aim of this study was to determine risk factors, infectious pathogens in blood and oral cavity of oral cancer patients undergoing different treatment procedures.

Methods: The present prospective cohort analysis was conducted on the patients undergoing treatment in the radiotherapy unit of Regional Cancer Institute, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, during the period of January 2007 to October 2009. Total 186 patients with squamous cell carcinoma of oral cavity were analyzed in the study. Based on treatment procedures patients were divided into three groups, group I were under radiotherapy, group II under chemotherapy and group III were of radio chemotherapy together. Clinical isolates from blood and oral cavity were identified by following general microbiological, staining and biochemical methods. The absolute neutrophil counts were done by following the standard methods.

Results: Prevalent bacterial pathogens isolated were *Staphylococcus aureus*, *Escherichia coli*, *Staphylococcus epidermidis*, *Pseudomonas aeruginosa*, *Klebsiella pneumonia*, *Proteus mirabilis*, *Proteus vulgaris* and the fungal pathogens were *Candida albicans*, *Aspergillus fumigatus*. The predominant gram negative bacteria, *Pseudomonas aeruginosa* and *Klebsiella pneumonia* were isolated from blood of radiotherapy and oral cavity of chemotherapy treated cases respectively. The predominance of gram positive bacteria (*Staphylococcus aureus* and *Staphylococcus epidermidis*) were observed in blood of chemotherapy, radio chemotherapy cases and oral cavity of radiotherapy, radio chemotherapy treated cases. Our study also revealed the presence of *C. albicans* fungi as most significant oral cavity pathogens in radiotherapy and radio chemotherapy cases.

Conclusion: Gram positive bacteria and Gram negative were reported from the blood of all the three groups of patients. Oral mucositis played a significant role in oral cavity infection and make patients more prone to *C. albicans* infection.

Background

Cancer patients remain at substantial risk for developing serious infections despite significant advances in cancer therapy and supportive care. The treatment of malignant conditions with cytotoxic chemotherapy and radiation therapy has become increasingly effective, but it is associated with significant side effects, including toxicities to haemopoietic and non-haematopoietic tissues. Similarly

neutropenia is still the most common pre-disposing factor, it is often superimposed on other immunological deficits (e.g. impaired cellular or humoral immunity) each of which is associated with a specific spectrum of infection. Bacterial infections predominate during the early phases of a neutropenic episode, whereas fungal infections occur more often in patients with prolonged neutropenia [1,2]. Beside neutropenia the chemotherapeutic agents and therapeutic radiation also disrupt the mucosal barrier of the mouth, leading to severe oral mucositis, gingivitis, oral candidiasis, cellulitis and viral mucosal eruptions [3-10]. The oral mucositis or

* Correspondence: yadav1964@rediffmail.com

†Equal contributors

¹Department of Genetics, M. D. University, RohtakHaryana, India
Full list of author information is available at the end of the article

inflammation of the oral mucosa is painful and is characterized by erythema, edema, and mucosal shedding, which can lead to ulceration and secondary infection [11,12]. Moreover, the oral cavity infections in cancer patients usually result from the combination of neutropenia and mucositis. In oral cavity infection the oral micro flora may be subsequently replaced by potentially pathogenic microorganisms, such as *Candida* sp., (from 72% to 92%), *Candida* carriage was reported common in cancer patients, with *C. albicans* being the predominant species in patients who undergo radiotherapy for Head and neck [13-17]. Oral colonization (up to 93%) and infection (up to 30%) are frequently noted in the patients [18]. The main reason is that the irradiation-induced histological changes leading to oral mucositis, together with salivary quantitative and qualitative changes, have been reported to facilitate yeast growth [13,19]. Beside that a possible explanation for the higher predisposition of irradiated patients to candidosis is due to reduced phagocytic activity of salivary granulocytes against these micro-organisms [20].

Similar to oral cavity infection, bloodstream infections (BSI) also remain serious complications in patients receiving antineoplastic therapy [21]. Bloodstream infections (BSIs) occur due to the failure of the immune system and consequently disseminated the disease. The frequency of BSI infections, their epidemiology, and the invading organisms have changed in parallel with the evolution of medical care, particularly with the emergence of an increasingly ill and immunocompromised population of hospitalized patients who are often heavily dependant on medical support and indwelling devices [22,23]. Currently, slightly more than 50% of BSIs are hospital acquired [24-28].

So, because of a weakened line of defense in oral cancer patients, the present prospective cohort study was carried out, with the aim of isolation, and identification of bacterial, fungal colonization from oral cavity and blood of radiotherapy, chemotherapy and radio chemotherapy treated patients. It is also important to be mentioned that our study was based on evaluation of colonization of fungal species only and did not consider the clinical aspects of the fungal species.

Methods

Study design

The present prospective cohort analysis was conducted on the patients undergoing treatment in the radiotherapy unit of Regional Cancer Institute, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, during the period of January 2007 to October 2009. A total of 186 patients with squamous cell carcinoma of oral cavity were analyzed in the study. The present study was approved by Human Ethical Committee of the

University (M.D. University, Rohtak) and written consent was also taken from the patients.

Patient's population

The patients were divided into three groups depending on their treatment protocol; each category was having 62 cases. First group patients were radiotherapy treated (RT) only (total dose of radiotherapy ranging from 51 to 60 grays in dose of 200cGY/day, 5 days a week), second group patients were given chemotherapy treated (CT) only (3 or 4 Courses of carboplatin, 5-FU, docetaxel/methotrexate/cisplatin given after 21 days gap) and third category patients were given radio chemotherapy simultaneously (RCT) (Between irradiation, chemotherapy courses of paclitaxel, carboplatin and 5-FU given).

Inclusion criteria

About 10^8 CFU/ml of bacteria and 10^5 CFU/ml of fungi cells were considered as pathogenic for the study. The main predisposing factors that can cause oral cavity and blood stream infection in the three studied groups were following:

Bloodstream infection (BSI): BSIs were defined, as isolation of a recognized pathogen (aerobic bacteria and fungi) from one or more blood cultures (BCs) that were unrelated to an infection at another site with, or without fever or hypotension [29,30].

Oral infection: Oral infection was defined as, isolation of recognized pathogens (aerobic bacteria and fungi) from one or more oral swab.

Episodes of BSI: Since any given patients could have a BSI more than once, so we use the term episode of BSI for each separate event [29,30].

Episode of bacteremia: The isolation of one bacteremia (unimicrobial) or more (polymicrobial) microorganisms in the same blood culture or in a separate blood culture obtained within 24–48 hours [29,30].

Neutropenia: Neutropenia was defined as, an ANC of less than 500 neutrophil/ μ L that may increase susceptibility to infection [29, 30].

Fever: Oral temperature of $\geq 38.5^\circ\text{C}$ or more within a 24-hours period after initiation of therapy [29,30].

Anemia: A pathologic deficiency for oxygen-carrying hemoglobin in the red blood cells. In case of males Hb. < 14 g/dl and in case of females Hb. < 12 g/dl were considered as anemic cases [31].

Community acquired infection: Any infection acquired before, or within 48 hours of admission to hospital and which was not related to any hospital procedure [29,30].

Nosocomial Infection: Nosocomial infection was defined as, at least one blood culture positive for significant pathogens in patients before, or within 48 hours of admission to hospital [29,30].

Catheter related infection: Infection was considered catheter related when at least one of following conditions were, meet (1) Isolation of same pathogens from catheter tip and blood. (2) Isolation of pathogens from a blood culture obtained from the catheter, but not from another blood obtained from peripheral vein at the same time [29,30].

Oral mucositis: WHO describe oral mucositis into 4 categories, like: grade 0- no change; grade 1 soreness/erythema; grade 2 erythema, ulcers, can eat solids; grade 3 ulcers, requires liquid diet only; grade 4 alimentionation not possible [30].

Exclusion criteria

Patients were excluded from the study if they had clinical or microbiological evidence of bloodstream infection of unknown origin. Patients who developed, fever within 24 hours after administration of chemotherapy and fever subsided within next 24 hours after completion of chemotherapy were also excluded from study. Common skin isolates, including *Coryneforms* and *Bacillus* species excluded from analysis. Coagulase negative *Staphylococci* (CoNS) were only considered as causative pathogens if two or more blood samples drawn on separate occasions showed the growth of the pathogen.

Clinical and laboratory data

The data on patient's age, sex, underlying cancer, clinical stage of cancer, medications (antibiotics, cytotoxic drugs), fever, and exposure to radiotherapy or chemotherapy were recorded over the preceding 30 days and an invasive procedure performed over the proceeding 10 days. For every febrile episode of oral infection and blood cavity infection, the data on: date of onset, date of admission, sources of infection, presence of venous catheters and period of their insertion, result of complete blood count, severity and duration of neutropenia were collected.

Oral cavity specimen handling

Before antibiotics were started, Oral swab were taken by gently rubbing a sterile cotton swab over the labial mucosa, tongue and cancerous lesion [32]. The swabs were incubated in sheep blood agar, saboured dextrose agar, macconkey agar, nutrient agar, and other selective media for primary isolation of the pathogens. These plates were than aerobically incubated for 24–48 hours at 37°C temperature for bacterial pathogens isolation and for 24–72 hours at 30°C in B.O.D. incubator for fungal species isolation.

Blood Specimen handling

Before antibiotics were started, blood samples (5 ml each) for cultures were obtained from each patient who developed, fever within 21 days following radiotherapy, chemotherapy and radio chemotherapy. One samples

isolated from central venous catheter (if present) and other from peripheral vein. Blood cultures were drawn with a sterile system after a sterile pad was placed below the catheter hub and the hub was disinfected with 10% povidone–iodine. Blood samples were than transferred in culture bottles of brain heart infusion broth. Bottles were incubated at 37°C for 7 days. Simultaneously bottles showing positive growth index from blood culture were gram stained and sub cultured on sheep blood agar, saboured dextrose agar, macconkey agar and nutrient agar, simmon citrate agar and cetrimide agar plates. These plates were than aerobically incubated for 24–48 hours at 37°C temperature for bacterial pathogens isolation and for 24–72 hours at 30°C in B.O.D. incubator for fungal species isolation.

Microbial identifications

The bacterial pathogens were identified after appearance of growth on sub cultured, plates of blood and oral swab by standard microbiological and biochemical procedures. These biochemical tests include: Carbohydrates fermentation tests, urease tests, oxidase test, haemolysis of blood, catalase test, motility tests and growth pathogens on specific media etc. A preliminary examination of fungal colony on SDA was done through gram stained, smear, formation of germ tube, study of micro morphology, morphology on KOH stained smear, assimilation of carbon and nitrogen [33-36].

All isolated pathogens were compared with MTCC standard strains like *S. aureus* with MTCC 96 strain, *S. epidermidis* MTCC 435 strain, *P. vulgaris* MTCC 426 strain, *P. mirabilis* MTCC 425 strain, *E. coli* MTCC 443 strain, *K. pneumonia* MTCC 109 strain, *P. aeruginosa* MTCC 741 strain, *C. albicans* 3017 strain and *A. fumigatus* 2550 strain.

Absolute neutrophils count

The absolute neutrophils count (ANC) was done by multiplying the total WBC count by percentage of neutrophils (segmented + band) [37].

$$\text{ANC} = \text{WBC} \times \text{percentage of neutrophils}$$

On the basis of ANC the patients were divided into two categories:

Neutropenia: When ANC was less than 500 (severe risk of infection).

Non neutropenia: When ANC was more than 500 (moderate risk of infection).

Basic statistical methods

Means values were reported \pm standard deviation (SD). Continuous variables mean values were compared by 't' tests. For independent samples difference in proportion

of two groups were compared by chi – square test (with Yates correction) or Fisher’s exact test, when appropriate. All test of significance were two tailed. Alpha was set at 0.05. For the logistic regression odd ratio with 95% confidence interval (CI₉₅) were calculated. Univariate analysis of dichotomous and ordinal variables was performed by using the procedures for matched data sets in the EpiInfo computer Programme (Epi 6.03: centre for disease control and prevention, USA). Conventional statistical methods were used to calculate means and standard deviation with the help of Microsoft excel 2007.

Results

Patients and their characteristics

In this study a total of 186 cases of oral squamous carcinoma divided into three groups have been taken into account. Group I patients had a median age of 60 years (range 25–83 years), with male- female ratio 45:17. Group II patients were having a median age of 45 years (range 30–65 years) with male -female ratio 47:15, and Group III patients were of median age of 50 years (range 48–65 years) with male -female ratio 50:12. Patients in all three groups were mainly of IIIrd and IVth clinical stage of cancer with predominant underlying disease carcinoma on base of tongue (Table 1).

Oral cavity infection

Predisposing factors of oral cavity infection in three groups have been shown in Table 2. In group 1 out of 62 patients, 35 (43.75%) clinical febrile episodes were found in 22 neutropenic and 45 (52.32%) from 40 non-neutropenic. The most significant risk factors of oral infection were found oral mucositis (grade 4) (P < .05). In case of group II, between 33 neutropenic cases, 46 (52.8%) febrile episodes of oral infection were isolated and from 29 non-neutropenic patients, 41(47.12%) episodes were isolated. And the prevalent significant predisposing factor was oral mucositis grade 3 (P < .05). In case of group III, between 44 neutropenic cases, 67 (63.8%) episodes of oral infection were isolated and from 18 non-neutropenic patients, 38 (36.19%) episodes were recovered and the most significant risk factor was mucositis grade 4 (P < .001).

The pathogens (%) isolated from oral cavity of all three groups have been shown in Tables 3. In group 1 out of 80 episodes, 143 pathogens were recovered, 136 pathogens were from 87 episodes of group II, and 175 pathogens were recovered from 105 episodes of group III.

The prevalent pathogens isolated from all three different groups have been shown in Table 3. In group 1 *C. albicans* was the most prevalent and significant fungi isolated from oral cavity after radiotherapy (P < .001). Gram positive bacteria were isolated from 6 (27.27%) febrile episodes, in neutropenic patients (13, 21.31%) and in

Table 1 Clinical and demographic data of 186 patients (62 cases per group)

Group I	
-Age in years, (median range)	60 (25–83)
-Underlying disease	
Carcinoma of oropharynx	12 (19.3%)
Carcinoma of floor of mouth	14 (22.5%)
Carcinoma of base of tongue	17 (27.4%)
Carcinoma of Tonsil Rt. Side	10 (16.1%)
Carcinoma of last molar tooth	9 (14.5%)
-Stage of cancer	
IInd	14 (22.5%)
IIIrd	17 (27.4%)
IVth	31 (50%)
-Male : Female ratio	45:17
Group II	
-Age in years, (median range)	45(30–65)
-Underlying disease	
Carcinoma of oropharynx	0
Carcinoma of floor of mouth	16 (25.8%)
Carcinoma of base of tongue	22 (35.4%)
Carcinoma of Tonsil Lt. Side	7 (11.29%)
Carcinoma of Larynx	17 (27.4%)
-Stage of cancer	
IInd	12 (19.3%)
IIIrd	25 (40.3%)
IVth	25 (40.3%)
-Male : Female ratio	47:15
Group III	
-Age in years, (median range)	50 (48–65)
-Underlying disease	
Carcinoma of oropharynx	13 (20.9%)
Carcinoma of floor of mouth	19 (30.64%)
Carcinoma of base of tongue	30 (48.3%)
Carcinoma of Tonsil Rt. Side	0
Carcinoma of last molar tooth	0
-Stage of cancer	
IInd	10 (16.1%)
IIIrd	22 (35.4%)
IVth	30 (48.3%)
-Male : Female ratio.	50:12

non-neutropenic patients (12, 14.63%). All gram negative bacteria (*E. coil*, *P. aeruginosa*, *K. pneumonia*, *P. mirabilis* and *P. vulgaris*) were isolated in almost in same number in oral infection. The polymicrobial episodes in oral infection were recovered in neutropenic cases (20, 57.14%) and in non neutropenic cases (5, 11.11%). In group II the oral infection causing pathogen was gram-negative bacteria

Table 2 Predisposing factors for oral cavity infection in febrile episodes of neutropenic and non- neutropenic patients in radiotherapy, chemotherapy and radio chemotherapy treated cases

Causative factors	Group = I		Group = II		Group = III	
	ANC		ANC		ANC	
	<500	≥500	<500	≥500	<500	≥500
Duration of neutropenia >7	4(6.55)	4(4.87)	4(5.06)	4(7.01)	4(4.34)	6(7.22)
	P = 0.72		P = .71		P = 0.52	
Oral mucositis (grade 0)	3(4.91)	3(3.65)	2(2.53)	4(7.01)	5(5.43)	2(2.40)
	P = 0.70		P = .23		P = .44	
Oral mucositis (grade 1)	4(6.55)	3(3.65)	3(3.79)	5(8.77)	7(7.60)	6(7.22)
	P = 0.45		P = 0.27		P = .84	
Oral mucositis (grade 2)	5(8.19)	5(6.09)	4(5.06)	5(8.77)	9(9.78)	4(4.81)
	P = .74		P = 0.49		P = .33	
Oral mucositis (grade 3)	8(13.11)	8(9.75)	19(24.05)	5(8.77)	11(11.95)	7(8.43)
	P = 0.71		P = 0.05*		P = .60	
Oral mucositis (grade 4)	9(14.75)	25(30.48)	11(13.92)	13(22.80)	32(34.78)	12(14.45)
	P < .05*		P = 0.26		P < .001***	
Anemia	4(6.55)	3(3.65)	5(6.32)	3(5.26)	5(5.43)	4(4.81)
	P = .45		P = 1		P = 1	
Central venous line present	6(9.83)	7(8.53)	9(11.39)	7(12.28)	7(7.60)	15(18.07)
	P = .97		P = .91		P = .06	
Peripheral line present	5(8.19)	3(3.65)	7(8.86)	5(8.77)	4(4.34)	9(10.84)
	P = .28		P = .77		P = .17	
Community acquired	6(9.83)	17(20.73)	6(7.59)	3(5.26)	3(3.26)	9(10.84)
	P = 0.12		P = .73		P = .09	
Nosocomial acquired	7(11.47)	4(4.87)	9(11.39)	3(5.26)	5(5.43)	9(10.84)
	P = .20		P = .34		P = 0.29	

Note: % had been shown in parenthesis, the value in table shows number of patients, ANC = absolute neutrophil count, ANC of < 500 neutrophil/micro L (neutropenic), ANC ≥ 500 neutrophil/micro L (non-neutropenic). P = Probability value with an ANC of < 500 neutrophil/micro L (neutropenic) vs. those with ANC > 500 neutrophil/micro L (non-neutropenic). P < .05 * less significant, P < .01 ** significant, P < .001 *** highly Significant.

(neutropenic 54.43% and non-neutropenic 57.89%) recovered from 20 neutropenic and 16 non-neutropenic febrile episodes. *K. pneumonia* was most prevalent and significant gram negative bacteria (P < .05). In gram positive bacteria *S. aureus* was the prevalent in neutropenic (18, 22.78%) and nonneutropenic cases (11, 19.29%). The pathogenic fungi were isolated from neutropenic (11, 13.92%) and non-neutropenic (6, 10.52%) patients. The polymicrobial infection was recovered from 14 episodes (30.4%) of 8 (24.24%) neutropenic cases and from 11 (26.8%) episodes of 11 (37.9%) non-neutropenic cases. In group III, 175 pathogens were isolated from 105 febrile episodes. The predominant isolated pathogens were gram positive bacteria recovered, 39 (42.39%) from 28 (53.84%) episodes of neutropenic and 31 (37.34%) pathogens from 15 (51.72%) episodes of non-neutropenic patients. The prevalent gram positive bacteria were *S. aureus* (P < .05) followed by *S. epidermidis* (P < .05). The gram-negative bacteria were isolated in higher amount from non-neutropenic (29, 34.93%) as compared to neutropenic cases (22, 23.91%). All gram negative pathogens were

isolated were same in number. *C. albicans* was significant isolated fungi (P < .05) recovered from neutropenic (33.69%), non-neutropenic (27.71%) cases. The Polymicrobial pathogens were isolated from 15 (22.38%) episodes and 9 (23.6%) episodes from non-neutropenic patients.

Blood streams infection

Predisposing factors for blood infection have been shown in Table 4. In group I out of 62 patients, 35 (43.75%) clinical febrile episodes were found in 22 neutropenic and 45 (52.32%) from 40 non-neutropenic. The most significant risk factors were found oral mucositis (grade 4) (P < .01), followed by community acquired infection (P < .05). In case of group II, between 33 neutropenic cases, 46 (52.8%) febrile episodes of bloodstream infection were isolated and from 29 non-neutropenic patients, 41(47.12%) of febrile episodes were isolated and no significant risk factor was observed. In case of group III, out of 44 neutropenic cases, 67 (63.8%) febrile episodes and out of 18 non-neutropenic patients, 38 (36.19%) of febrile episodes were recovered. The most

Table 3 Predominant pathogens isolated from oral cavity of neutropenic and non-neutropenic patients treated with radiotherapy, chemotherapy and radiochemotherapy (Group I, II, III)

Pathogens	ANC (<500) ANC (>500)				ANC (<500) ANC (>500)				ANC (<500) ANC (>500)			
	n = 61	n = 82	OR (95 % C.I.)	P	n = 79	n = 57	OR (95 % C.I.)	P	n = 92	n = 83	OR (95 % C.I.)	P
(A)Gram + ive	13(21.3)	12(14.6)	1.58(0.61-4.0)	0.41	25(31.6)	18(31.5)	1.00(0.45-2.2)	0.85	39(42.3)	31(37.3)	1.23(0.6-2.3)	0.59
<i>S. aureus</i>	8(13.1)	6(7.3)	1.60(0.25-10.7)	0.85	18(22.7)	11(19.2)	1.64(0.38-7.2)	0.67	29(31.5)	15(18)	3.09(1.0-9.6)	<0.05*
<i>S. epidermidis</i>	5(8.1)	6(7.3)	0.63(0.09-4.0)	0.85	7(8.8)	7(12.28)	0.61(0.14-2.2)	0.67	10(10.8)	16(19.2)	0.32(0.1-0.9)	<0.05*
(B)Gram -ive	20(32.9)	18(21.9)	1.25(0.57-2.7)	0.68	43(54.4)	33(57.8)	0.87(0.41-1.8)	0.82	22(23.9)	29(34.9)	0.59(0.2-1.1)	0.15
<i>E. coli</i>	4(6.5)	6(7.3)	0.50(0.09-2.6)	0.46	7(8.8)	8(14.3)	0.61(0.17-2.1)	0.56	6(6.5)	8(9.6)	0.98(0.2-4.0)	.77
<i>P. aeruginosa</i>	3(4.9)	4(4.8)	0.62(0.09-4.1)	0.68	5(6.3)	4(7)	0.95(0.20-4.7)	1.00	5(5.4)	7(8.4)	0.92(0.2-4.0)	0.82
<i>K. pneumonia</i>	5(8.1)	5(6.0)	0.87(0.16-4.5)	1	27(34.1)	13(22.8)	2.60(0.93-7.3)	< 0.05*	4(4.3)	5(6)	1.07(0.2-5.5)	1
<i>P. mirabilis</i>	5(8.1)	3(3.6)	3(0.41-26.4)	0.40	4(5.0)	6(10.5)	0.46(0.10-2.1)	0.31	4(4.3)	5(6)	1.07(0.2-5.5)	1
<i>P. vulgaris</i>	3(3.8)	0	UN	0.23	0	2(3.5)	0.00(0.00-3.14)6	0.18	3(3.2)	4(4.8)	0.99(0.1-6.1)	1
(C) Fungi	28(45.9)	52(63.4)	0.49(0.24-1.0)	< 0.05*	11(13.9)	6(10.5)	1.38(0.43-4.5)	0.74	31(33.6)	23(27.7)	1.33(0.6-2.6)	0.48
<i>C. albicans</i>	28(45.9)	40(48.7)	1.30 (1.12-1.5)	< .001***0	7(8.8)	6(10.5)	0.00(0.00-2.8)	0.23	26(28.2)	23(27.7)	0.00(0.0-1.5)	<.05*
<i>A. fumigatus</i>	0	12	UN	.02	4(5.0)	0	UN	1.0	5(5.4)	0	UN	1

Note: n = number of pathogens, UN: Undefined, % had been shown in parenthesis, ANC = absolute neutrophil count, ANC of <500 neutrophil/micro L (neutropenic), ANC >500 neutrophil/micro L (non-neutropenic). P = Probability value with an ANC of <500 neutrophil/micro L (neutropenic) vs. those with ANC >500 neutrophil/micro L (non-neutropenic). P < .05 * less significant, P < .01 ** significant, P < .001 *** highly significant.

Table 4 Predisposing factors for bloodstream infection in febrile episodes of neutropenic and non- neutropenic patients in radiotherapy, chemotherapy and radio chemotherapy treated cases

Causative factors	Group = I		Group = II		Group = III	
	ANC		ANC		ANC	
	<500	≥500	<500	≥500	<500	≥500
Duration of neutropenia >7	5(7.81)	4(4.70)	6(6.6)	4(7.27)	10(8.92)	6(6.31)
	P = 0.49		P = 1		P = 0.65	
Oral mucositis (grade 0)	5(7.81)	3(3.52)	5(5.55)	4(7.27)	5(4.46)	2(1.78)
	P = 0.28		P = .73		P = .45	
Oral mucositis (grade 1)	6(9.37)	3(3.52)	2(2.22)	5(9.09)	7(6.25)	6(6.31)
	P = 0.17		P = 0.10		P = .78	
Oral mucositis (grade 2)	4(6.25)	5(5.88)	4(4.44)	5(9.09)	12(10.71)	4 (4.21)
	P = 1		P = 0.30		P = .13	
Oral mucositis (grade 3)	5(7.81)	8(9.41)	9(10)	6(10.90)	15(13.39)	7(7.36)
	P = 0.78		P = 0.91		P = .23	
Oral mucositis (grade 4)	7(10.93)	25(29.41)	11(12.22)	12(21.81)	32(28.57)	12(12.63)
	P < .01**		P = 0.19		P < .001***	
Anemia	4(6.25)	3(3.52)	10(11.11)	3(5.45)	9(8.03)	6(6.31)
	P = .46		P = .37		P = .83	
Central venous line present	8(12.5)	7(8.23)	15(16.6)	5(9.09)	7(6.25)	15(15.78)
	P = .56		P = .30		P = .05*	
Peripheral line present	5(7.81)	3(3.52)	9(10)	5(9.09)	4(3.57)	10(10.52)
	P = .02		P = .91		P = .08	
Community acquired	6(9.37)	20(23.52)	6(6.06)	2(3.63)	6(5.35)	11(11.57)
	P < .05*		P = .71		P = .17	
Nosocomial acquired	9(14.06)	4(4.70)	13(14.44)	4(7.27)	5(4.46)	16(16.84)
	P = .08		P = .29		P < .001***	

Note: % had been shown in parenthesis, the value in table shows number of patients, ANC = absolute neutrophil count, ANC of <500 neutrophil/micro L (neutropenic), ANC ≥500 neutrophil/micro L (non-neutropenic). P = Probability value with an ANC of <500 neutrophil/micro L (neutropenic) vs. those with ANC >500 neutrophil/micro L (non-neutropenic). P < .05 * less significant, P < .01 ** significant, P < .001 *** highly Significant.

prevalent significant risk factor was nosocomial acquired infection (P < .001), followed by mucositis grade 4 (P < .001) and central venous line (P < .05).

The pathogens (%) isolated from blood of all three groups have been shown in Table 4. During the study a total of 149 pathogens were recovered from 80 febrile episodes of BSI from group I, 145 pathogens from 87 febrile episodes from group II and 207 pathogens were recovered from 105 febrile episodes in group III.

In group I gram negative bacteria were recovered from 16 (57.14%) febrile episodes of patients, in neutropenic 26 (40.62%) and 56 (65.80%) in non-neutropenic patients (P < .001). *P. aeruginosa* was the most significant (P < .05) gram negative bacterium. Gram positive bacteria were isolated from, 8 (28.5%) febrile episodes, 23 (35.93%) in neutropenic patients and 18 (21.17%) in non-neutropenic patients. *C. albicans* was predominant in neutropenic 9 (14.06%) and nonneutropenic 6 (7.05%) patients. Out of all febrile episodes of neutropenic and non- neutropenic, 7 episodes (20%, 15.5%) were polymicrobial. In case of group II the main pathogens were gram-positive bacteria

isolated in 25 (45.45%) febrile episode of neutropenic (57.77%), and 26 (40%) febrile episode of non-neutropenic 35 (62.85%) patients. Gram-negative bacteria were isolated, 24 (26.26%) from 10 (25%) febrile episodes in neutropenic and 22 (40%) from 9 (25.71%) febrile episode in non-neutropenic patients. Pathogenic fungi isolated from neutropenic and non-neutropenic patients were 14 (15.5) and 8 (14.54%). A total of 5 cases (15.15%) in 6 episodes (13.04) were polymicrobial in neutropenic patients and 4 cases (13.7%) in 6 episodes (14.6%) were in non-neutropenic cases. In case of group III 207 pathogens were isolate from 105 febrile episodes. Out of 37 febrile episodes of neutropenic and 17 febrile episodes of non neutropenic cases the most significant isolated pathogen (P < .01) were gram-positive bacteria. The gram-negative bacteria were found higher in nonneutropenic cases (42, 44.21%) as compared to neutropenic cases 39 (34.82%). The fungi isolated from neutropenic patients, 10.71% and 18.94% from non-neutropenic patients. The polymicrobial BSI infection was reported from 16 episodes (23.8%) of neutropenic and 12 episodes, (31.5%) of non neutropenic patients.

Table 5 Predominant pathogens isolated from blood of neutropenic and non-neutropenic patients treated with radiotherapy, chemotherapy and radio-chemotherapy (Group I, II, III)

Pathogens	ANC (<500)				ANC (>500)				ANC (<500)				ANC (>500)			
	n = 64	n = 85	OR (95 % C.I.)	P	n = 90	n = 55	OR (95 % C.I.)	P	n = 112	n = 95	OR (95 % C.I.)	P	n = 112	n = 95	OR (95 % C.I.)	P
(A)Gram + ive	23(35.9)	18(21.1)	2.09(0.95-4.6)	0.07	52(5.7)	25(45.4)	1.64(0.7-3.4)	0.20	61(54.4)	35(36.8)	2.0(1.1-3.7)	< 0.01**	61(54.4)	35(36.8)	2.0(1.1-3.7)	< 0.01**
<i>S. aureus</i>	15(23.4)	12(14.1)	0.94(0.21-4.1)	0.81	42(4.6)	11(2)	5.35 (1.6-17.6)	< .001**	21(18.7)	28(29.4)	0.1(0.0-0.3)	< .001***	21(18.7)	28(29.4)	0.1(0.0-0.3)	< .001***
<i>S. epidermidis</i>	8(12.5)	6(7.0)	1.07(0.24-4.7)	0.81	10(1.1)	14(25.4)	0.19(0.0-0.6)	< .001**	40(35.7)	7(7.3)	7.6(2.6-23.1)	< .001***	40(35.7)	7(7.3)	7.6(2.6-23.1)	< .001***
(B)Gram -ive	26(40.6)	56(65.8)	0.35(0.1-0.7)	< 0.001***	24(2.6)	22(4)	0.55(0.2-1.1)	0.13	39(34.8)	42(44.2)	0.67(0.3-1.2)	0.21	39(34.8)	42(44.2)	0.67(0.3-1.2)	0.21
<i>E. coli</i>	10(15.6)	9(10.5)	0.34(0.1-0.9)	0.04	7(7.7)	6(10.9)	1.10(0.2-4.7)	0.85	11(9.8)	17(17.8)	0.58(0.2-1.6)	0.35	11(9.8)	17(17.8)	0.58(0.2-1.6)	0.35
<i>P. aeruginosa</i>	6(9.3)	28(32.9)	0.30(0.0-0.9)	< 0.05*	7(7.7)	7(12.7)	0.88(0.2-3.7)	0.90	12(10.7)	12(12.6)	1.11(0.3-3.2)	0.97	12(10.7)	12(12.6)	1.11(0.3-3.2)	0.97
<i>K. pneumonia</i>	5(7.8)	14(16.4)	0.71(0.1-2.5)	0.76	6(6.6)	5(9.0)	1.13(0.2-5.4)	0.86	10(8.9)	7(7.3)	1.72(0.5-5.8)	0.47	10(8.9)	7(7.3)	1.72(0.5-5.8)	0.47
<i>P. mirabilis</i>	5(7.8)	5(5.8)	2.43(0.5-11.1)	0.27	4(4.4)	3(5.4)	1.27(0.2-8.4)	1.00	4(3.5)	5(5.2)	0.85(0.1-4.0)	1	4(3.5)	5(5.2)	0.85(0.1-4.0)	1
<i>P. vulgaris</i>	0	0	0	0	0	1(1.8)	0.00(0.0-16.4)	0.47	2(1.7)	1(1.0)	1.84(0.1-53.7)	1	2(1.7)	1(1.0)	1.84(0.1-53.7)	1
(C) Fungi	15(23.4)	11(12.9)	2.06(0.8-5.2)	0.14	14(15. 5)	8(14.5)	1.20(0.4-3.3)	0.88	12(10.7)	18(18.9)	0.51(0.2-1.2)	0.13	12(10.7)	18(18.9)	0.51(0.2-1.2)	0.13
<i>C. albicans</i>	9(14.0)	6(7.0)	1.25(0.2-8.0)	1.00	8(8.8)	5(9.0)	0.80(0.0-6.5)	1.00	7(6.2)	10(10.5)	1.12(0.2-6.3)	0.82	7(6.2)	10(10.5)	1.12(0.2-6.3)	0.82
<i>A. fumigatus</i>	6(9.3)	5(5.8)	0.80(0.1-5.0)	1.00	6(6.6)	3(5.4)	1.25(0.1-10.5)	1.00	5(4.4)	8(8.4)	0. 89(0.1-4.9)	0.82	5(4.4)	8(8.4)	0. 89(0.1-4.9)	0.82

Note: n = number of pathogens, % had been shown in parenthesis, ANC = absolute neutrophil count, ANC of <500 neutrophil/micro L (neutropenic), ANC > 500 neutrophil/micro L (non-neutropenic). P = Probability value of patients with an ANC of <500 neutrophil/micro L (neutropenic) vs. those with ANC >500 neutrophil/micro L (non-neutropenic). P < .05 * less significant, P < .01 ** significant, P < .001 *** highly significant.

Discussion

This prospective cohort study is first from Haryana, India and is based on evaluation of the rate, risk factors and outcomes of treatment procedures between oral cancer patients. The present report describes colonization of bacterial and fungal infectious pathogens in oral cancer patients.

The colonization of microorganisms in cancer patients was found to occur in oropharynx as well as gastrointestinal system, urinary system and airways. Colonization starts within 48 hours of hospitalization [38]. Number of studies proved that Neutropenia increases the microbial colonization [39-41]. Our observation also illustrates that the colonization of microorganisms was higher in blood and oral cavity of neutropenic cases after chemotherapy, radio chemotherapy.

Nowadays, in most of hospitals, there is a shift of the microbial spectrum of cancer patients from gram-negative to gram positive, compared with the predominance of gram-negative species in the 1960s and 1970s [42-46]. Nevertheless in developing countries there is a different situation where the predominant pathogens are gram-negative, the reason maybe the people cannot afford to give routinely prophylactic oral antibiotics, such as quinolones, and use less central lines. The predominance of gram negative bacteria in developing countries can also be explained with the help of various studies. A study was conducted on febrile neutropenic patients in a hospital from Lebanon and observed that the gram-negative bacteria were responsible for 78.8% (26/33) of bloodstream infections compared to 33.3% (11/33) gram-positive organisms. In the present study dominant gram negative bacteria were of *E. coli* and *P. aeruginosa*. A possible explanation of the observed high incidence of gram-negative infections in Lebanon was the relatively low proportion of indwelling catheters [47]. Another study was carried in Malaysia observed that out of 120 episodes, 60.02% were gram-negative organisms of Enterobacteriaceae [48]. A similar pattern of predominant gram-negative bacteria (61%) was seen in a study of hematologic malignancy patients from Brazil [49]. Similar to above study we have also observed that main pathogen isolated from blood of group I and oral cavity of group II were of gram negative bacteria. This may be due to absence of use of catheter as a routine practice during the period of our analysis.

In our study *P. aeruginosa* was the main gram negative bacteria in blood stream and *K. pneumonia* was in oral cavity. Similar to our study the presence of *P. aeruginosa* as an infectious pathogen was also observed by Raje et al., [50]. They reported *P. aeruginosa* (28%) as a major pathogen in febrile neutropenic patients of acute lymphoblastic leukemia cases. Karim et al., [51] and Saghie et al., [52] were also observed presence of *P. aeruginosa* in 31% and 38% respectively from febrile neutropenic cases. However

our study showed the proportion of *P. aeruginosa* was higher in non- neutropenic cases.

The present report also revealed the predominance of gram positive bacteria (*S. aureus* and *S. epidermidis*) in blood of group II, III and oral cavity of I, III group. The predominance of gram positive bacteria as infectious pathogen was also proved by other studies did in India. Jagarmuldi et al., [43] conducted a study on acute leukemia cases and observed 38.5% of *S. aureus* infection in 240 febrile episodes and in other study *S. aureus* (39%) infection was observed in blood after chemotherapy [53]. The prevalence of gram positive bacteria may be due to that oral cancer patient were undergone treatment of high intensive chemotherapy, radio chemotherapy which may be led to damage of the mucosal barriers and increases the risk of infection with gram-positive oral (and GI) flora [54]. In favor of that reason, we observed the significant predisposing factor for blood stream infection was the use of central venous line ($P < .05$) in group III, which may be facilitated the entry of organisms colonizing the skin into the bloodstream, and thus increase the rate of Staphylococcal infections in blood and oral cavity [2,43]. Our study also observed another significant predisposing factor of bloodstream infection in group III was nosocomial acquired ($P < .01$). The role of nosocomial acquisition of *S. aureus* infection was also demonstrated in various studies did at five centers in Egypt and a provincial hospital in north east Thailand [55,56]. Nosocomial infection of *S. aureus* in developing countries is probably common, the reasons for which may include lack of hand washbasins or hand washing, overcrowding in hospital wards and clinics, lack of infection control training or policies, the inability to isolate specific patients, and lack of diagnostic microbiology facilities [56].

Another salient featured of our study was the colonization of *C. albicans* as most significant oral cavity pathogens in group I and III patients. *C. albicans* was isolated in group I neutropenic, non neutropenic cases in proportion of 45.90%, 48.78% respectively and in group III its proportion in neutropenic, non neutropenic cases was 28.2%, 27.72% respectively. The proportion of *C. albicans* in group I i.e. radiotherapy treated, cases was similar to various studies conducted on oral candidiasis after radiotherapy and showed a wide variation ranging from 17 to 52.5% [4,17,19,57-60]. The colonization of *C. albicans* in oral cavity of radiotherapy treated, cases may be due to the reason that our patients were often unable to maintain satisfactory oral health and nutritional status during RT, mainly because of low income and educational level. This reasons of colonization of *C. albicans* in oral cavity was also observed in study did in Brazilian patients undergoing head and neck radiotherapy [17]. The pathogenesis of candidal infections is complex encompassing both fungi and host factors. Candidal colonisation appears to be influenced by adherence mechanisms among fungi and oral

epithelial cells. Radiotherapy-induced hyposalivation also encourages oral candidal colonization that often leads to oral candidiasis [19].

We have also observed other reason of colonization of *C. albicans* may be oral mucositis, which played a significant role in oral cavity infection of all three groups. Generally it is also accepted that oral mucositis, is of multifactorial origin, and it is ranged among 20% and 100% in patients receiving different types of cancer treatments [61-65]. Other reason for the prevalence of mucositis in our study may be due to fluorinated 5-fluorouracil (5-FU) which was the most effective and frequently used antineoplastic agent for the treatment of oral cancer. There are others reports which also showed mucositis (4 to 74% for head and neck cancers) induced by 5-FU [66,67].

Some limitations were present in our study, first was that we did not take the clinical features of Oral candidosis in our patients i.e. we were not able to evaluate that whether the Oral candidiasis remain confined to the oral cavity, or spread to oesophageal or more widely to cause systemic candidosis. This study also is limited to infections caused by aspergillosis and candidiasis. Although these two pathogens represent most of fungal infections, infections due to other fungal species may result an additional burden to the oral cancer cases.

Conclusion

Radiotherapy and chemotherapy have been widely used for the treatment of malignant lesions in oral cancer patients to increase the survival rates. However, these therapies are still associated with several adverse reactions that affect patient quality of life significantly, and may even affect the progress of the treatment. Taking into account that the occurrences of oral cancer rates are probably going to be the increase in near future, it is extremely important that health professionals are familiarized with the complications from anti-neoplastic treatments. The present study revealed that radio and chemotherapy treated immunocompromised patients are prone to bacterial and fungal infection with predominance of gram positive bacteria. This study also revealed the presence of *C. albicans* fungi as most significant oral cavity pathogens in radiotherapy and radio chemotherapy treated patients. So the multidisciplinary treatment, including medical team, dental surgeons, speech therapists, nutritionists and psychologists, is the best option to minimize or even prevent such complications in oral cancer cases.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors have equal contribution in study designs, experiment, data analysis and interpretation of data. Similarly all authors have critically

reviewed the manuscript, approved of its contents and consented to its communication for publication.

Acknowledgements

We are thankful to the M.D. University, Rohtak for providing the fellowships to Ms. Manju Panghal for this research work. We are also thankful to Haryana state government for providing us financial grants for necessary facilities.

Author details

¹Department of Genetics, M. D. University, RohtakHaryana, India.

²Department of Radiotherapy, Regional Cancer Institute, Pt. B.D.S, Health University, RohtakHaryana, India.

Received: 22 October 2011 Accepted: 27 June 2012

Published: 20 July 2012

References

1. Chatzinikalaou I, Abi-Said D, Bodey GP, Rolston KVI, Tarrand JJ, Samonis G: Recent experience with *Pseudomonas aeruginosa* bacteremia in patients with cancer Retrospective Analysis of 245 Episodes. *Archives Intern Med* 2000, **160**:501-509.
2. Rolston KV: The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. *Clin Infect Dis* 2004, **39**(Suppl 1):44-48.
3. Kanas RJ, Jensen JL, DeBoom GW: Painful oral mucosal ulcers in a patient with small cell carcinoma of the lung. *J Am Dent Assoc* 1987, **115**(1):75-76.
4. Redding SW, Zellars RC, Kirkpatrick WR, McAtee RK, Caceres MA, Fothergill AW, LopezRibot JL, Bailey CW, Rinaldi MG, Patterson TF: Epidemiology of Oropharyngeal Candida Colonization and Infection in Patients Receiving Radiation for Head and Neck Cancer. *J Clin Microbiol* 1999, **37**(12):3896-3900.
5. Paster BJ, Boches SK, Galvin JL, Ericson RE, Lau CN, Levanos VA: Bacterial diversity in human subgingival plaque. *J Bacteriol* 2001, **183**:3770-3783.
6. Trotti A, Bellm LA, Epstein JB: Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. *Radiother Oncol* 2003, **66**:253-262.
7. Sonis ST, Elting LS, Keefe D: Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. *Cancer* 2004, **100**:1995-2025.
8. Vera-Llonch M, Oster G, Hagiwara M: Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. *Cancer* 2006, **106**:329-336.
9. Nagy K, Urban E, Fazekas O: Controlled study of lactoperoxidase gel on oral flora and saliva in irradiated patients with oral cancer. *J Craniofac Surg* 2007, **18**:1157-1164.
10. Lalla RV, Latortue MC, Hong CH, Ariyawardana A, Amato D, Palumbo S, Fisher DJ, Martof A, Nicolatou GC, Patton LL, Elting LS, Spijkervet FK, Brennan MT: A systematic review of oral fungal infections in patients receiving cancer therapy. *Support Care Cancer* 2010, **18**(8):985-992.
11. Raber-Durlacher JE, Weijl NI, Abu Saris M, de Koning B, Zwinderman AH, Osanto S: Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. *Support Care Cancer* 2000, **8**:366-371.
12. Raber-Durlacher JE, Barasch A, Peterson DE, Lalla RV, Schubert MM, Fibbe WE: Oral complications and management considerations in patients treated with high-dose chemotherapy. *Support Cancer Therapy* 2004, **1**:219-229.
13. Silverman SJ, Luangjamekorn L, Greenspan D: Occurrence of oral Candida in irradiated head and neck cancer patients. *J Oral Med* 1984, **39**:194-196.
14. Leung WK, Dassanayake RS, Yau JYY, Jin LJ, Yam WC, Samaranyake LP: Oral colonization, phenotypic, and genotypic profiles of Candida species in irradiated, dentate, xerostomic, nasopharyngeal carcinoma survivors. *J Clin Microbiol* 2000, **38**:2219-2226.
15. Al-Abeid HM, Abu-Elteen KH, Elkarni AZ, Hamad MA: Isolation and Characterization of Candida Spp. In Jordanian cancer patients: Prevalence, Pthogenic Determinants, and Antifungal Sensitivity. *Jpn J Infect Dis* 2004, **57**:279-284.

16. Jham BC, Freire AR: **Oral complications of radiotherapy in the head and neck.** *Revista Brasileira de Otorrinolaringologia* 2006, **72**(5):704–708.
17. Jham BC, França EC, Oliveira RR, Santos VR, Kowalski LP, Silva Aa, Freire AR: **Candida oral colonization and infection in Brazilian patients undergoing head and neck radiotherapy: a pilot study.** *Oral Surgery Oral Medicine Oral Pathology Oral Radiology Endodontology* 2007, **103**:355–358.
18. Epstein JB, Freilich MM, Le ND: **Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck.** *Oral Surg Oral Med Oral Pathol* 1993, **76**:169–174.
19. Ramirez-Amador V, Silverman S Jr, Mayer P, Tyler M, Quivey J: **Candidal colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy.** *Oral Surg Oral Med Oral Pathol Radiol Endod* 1997, **84**:149–153.
20. Ueta E, Osaki T, Yoneda K, Yamamoto T: **Prevalence of diabetes mellitus in odontogenic infections and oral candidosis.** *J Oral Pathol Med* 1993, **22**:168–174.
21. Safdar A, Armstrong D: **Infectious morbidity in critically ill patients with cancer.** *Crit Care Clin* 2001, **17**:531–570.
22. Velasco E, Santos Thuler LC, Martins CA, Dias LM, Goncalves VM: **Nosocomial infections in an oncology intensive care unit.** *Am J Infect Control* 1997, **26**:458–462.
23. Simon A, Ammann RA, Bode U, Fleischhack G, Wenchel HM, Schwamborn D, Gravou C, Schlegel P, Rutkowski S, Dannenberg C, Korholz D, Laws HJ, Kramer MH: **Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland.** *BMC Infect Dis* 2008, **8**:70.
24. Bryan CS, Hornung CA, Reynolds KL, Brenner ER: **Endemic bacteraemia in Columbia, South Carolina.** *Am J Epidemiol* 1986, **123**:113–127.
25. Weinstein MP, Towns ML, Quartey SM: **The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults.** *Clinical Infectious Disease* 1997, **24**:584–602.
26. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J: **Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998, SENTRY Participants Group.** *Clin Infect Dis* 2000, **30**:454–460.
27. Simon A, Fleischhack G, Hasan C, Bode U, Engelhart S, Kramer MH: **Surveillance for nosocomial and central line related infections among pediatric hematology-oncology patients.** *Infect Control Hosp Epidemiol* 2000, **21**:592–596.
28. Kamboj M, Sepkowitz KA: **Nosocomial infections in patients with cancer.** *Lancet Oncol* 2009, **10**:589–597.
29. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: **CDC definitions for nosocomial infections.** *Am J Infect Control* 1988, **16**(3):128–140.
30. National Comprehensive Cancer Network (NCCN): **NCCN Clinical Practice Guidelines in Oncology, Prevention and Treatment of Cancer-Related Infections; 2007.**
31. Harrison LB, Chadhaa M, Hill RJ, Hu K, Shashaa D: **Impact of tumor hypoxia and anemia on radiontherapy outcomes.** *Journal of Oncologist* 2002, **7**(6):492–508.
32. Rautemaa R, Rusanen P, Richardson M, Meurma JH: **Optimal sampling site for mucosal candidosis in oral cancer patients is the labial sulcus.** *J Med Microbiol* 2006, **55**:1447–1451.
33. Shimeld LA: **Essential of Diagnostic Microbiology.** USA: International Thomas Publishing Company; 1998.
34. Hawkey P, Law D: **Medical Bacteriology.** New York: Oxford University Press; 2004.
35. Ryan KJ: **Normal Microbial flora.** In *Medical Microbiology.* Fourth edition. Edited by Sheris JC, Ryan KJ, Ray GC. USA: McGraw Hill; 2004.
36. Pawar VB, Dutta D: **From Diagnostic Bacteriology.** In *A procedure manual for routine diagnostic test.* Volume 2. Edited by Mukherjee KL. New Delhi: Tata MacGraw-Hill Publishing Company Limited; 2006:554–626.
37. Hughes WT, Armstrong D, Bodey GP: **Guidelines for the use of antimicrobial agents in neutropenic patients with cancer.** *Clin Infect Dis* 2002, **34**:730–751.
38. Jarvis WR: **Epidemiology of nosocomial fungal infections, with emphasis on *Candida* species.** *Clin Infect Dis* 1995, **26**:1526–1530.
39. Martino P, Girmenia C, Micozzi A: **Prospective study of *Candida* colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients.** *Eur J Clin Microbiol Infect Dis* 1994, **13**:797–804.
40. Amar S, Vishnu C, Emily W, et al: **Prospective study of candida species in patients at a comprehensive cancer center.** *Antimicrob Agents Chemother* 2001, **45**:2129–2133.
41. Senler FC, Cakmakci S, Akan OA, Demirkazik A, Akbulut HF: **Characteristics of Oropharyngeal Candida and Bacterial Colonization in Cancer Patients.** *International Journal of Hematology and Oncology* 2012, **22**:1–7.
42. Rolston KVI, Tarrand JJ: ***Pseudomonas aeruginosa*—still a frequent pathogen in patients with cancer: 11-year experience at a comprehensive cancer center.** *Clin Infect Dis* 1999, **29**:463–464.
43. Jagarlamudi R, Kumar L, Kapil A: **Infections in acute leukemia: an analysis of 240 febrile episodes.** *Med Oncol* 2000, **17**(2):111–116.
44. Wisplinghoff H, Seifert H, Wenzel RP, Edmond B: **Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States.** *Clin Infect Dis* 2003, **36**:1103–1110.
45. Raad I, Hachem R, Hanna H, Bahna P, Chatzinikolaou I, Fang X, Jiang Y, Chemaly RF, Rolston K: **Sources and outcome of bloodstream infections in cancer patients: the role of central venous catheters.** *Eur J Clin Microbiol Infect Dis* 2007, **26**:549–556.
46. Babay HA: **Bacterial isolates from fatal cases of bloodstream infection at a university hospital in central, Saudi Arabia.** *Saudi Med J* 2007, **28**(2):231–235.
47. Kanafani ZA, Dakdouki GK, El-Chammas KI, Eid S, Araj GF, Kanj SS: **Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade.** *Int J Infect Dis* 2007, **11**:450–453.
48. Baskaran ND, Gan GG, Adeeba K, Sam IC: **Bacteraemia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia.** *Int J Infect Dis* 2007, **6**:513–517.
49. Luzzaro F, Viganò EF, Fossati D: **Prevalence and drug susceptibilities of pathogens causing bloodstream infection in northern Italy: a two year study in 16 hospitals.** *Eur J Clin Microbiol Infect Dis* 2002, **21**:849.
50. Raje NS, Rao SR, Iyer RS, Kelkar RS, Pai SK, Nair CN, Kurkure PA, Magrath IT, Advani SH: **Infection analysis in acute lymphoblastic leukemia: a report of 499 consecutive episodes in India.** *Pediatr Hematol Oncol* 1994, **11**:271–280.
51. Karim M, Khan W, Farooqi B, Malik I: **Bacterial isolates in neutropenic febrile patients.** *J Pak Med Assoc* 1991, **41**:35–37.
52. Saghir S, Faiz M, Saleem M, Younus A, Aziz H: **Characterization and anti-microbial susceptibility of gram-negative bacteria isolated from bloodstream infections of cancer patients on Chemotherapy in Pakistan.** *Indian J of Medical Microbiology* 2009, **27**(4):341–347.
53. Bakshi S, Padmanjali KS, Arya LS: **Infections in childhood acute lymphoblastic leukemia: An analysis of 222 febrile neutropenic episodes.** *Pediatr Hematol Oncol* 2008, **25**(5):385–392.
54. Khan SA, Wingard JR: **Infection and Mucosal Injury in Cancer Treatment.** *J Natl Cancer Inst Monogr* 2001, **29**:31–36.
55. El Kholly A, Baseem H, Hall GS: **Antimicrobial resistance in Cairo, Egypt 1999–2000: A survey of five hospitals.** *J Antimicrob Chemother* 2003, **51**:625–630.
56. Nickerson EK, Wuthiekanun V, Wongsuvan G, Limmathurosakul D, Srisamang P: **Factors Predicting and Reducing Mortality in Patients with Invasive *Staphylococcus aureus* Disease in a Developing Country.** *PLoS One* 2009, **4**(8):1–8.
57. Nicolatou-Galitis O, Sotiropoulou-Lontou A, Velegraki A, Pissakas G, Kolitsi G, Kyprianou K, Kouloulas V, Papanikolaou I, Yiotakis I, Dardoufas K: **Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection.** *Oral Oncol* 2003, **39**:397–401.
58. Bagg J, Sweeney MP, Lewis MAO, Jackson MS, Coleman D, Al Mosaïd A, Baxter W, McEnderick S, McHugh S: **High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer.** *Palliative Medicine* 2003, **17**:477–481.
59. Belazi M, Velegraki A, Koussidou-Eremondi T, Andreadis D, Hini S, Arsenis G, Eliopoulou C, Destouni E, Antoniadis D: **Oral *Candida* isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.** *Oral Microbiol Immunol* 2004, **19**(6):347–351.

60. Davies AN, Brailsford SR, Beighton D: **Oral candidosis in patients with advanced cancer.** *Oral Oncol* 2006, **42**:698–702.
61. Schelenz S, Abdallah S, Gray G, Stubbings H, Gow I, Baker P, Hunter PR: **Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors.** *J Oral Pathol Med* 2011, **40**:83–89.
62. Blijlevens NM, Donnelly JP, De Pauw BE: **Mucosal barrier injury: Biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy—an overview.** *Bone Marrow Transplant* 2000, **25**:1269–1278.
63. Fu KK, Pajak TF, Trotti A: **A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.** *Int J Radiat Oncol Biol Phys* 2000, **48**:7–16.
64. Spiellberger B, Powers JH, Brass EP, Miller LG, Edwards JE: **Trends in antimicrobial drug development: implications for the future.** *Clin Infect Dis* 2004, **38**:1279–1286.
65. Scully C, Sonis S, Diz PD: **Oral mucositis.** *Oral Dis* 2006, **12**(3):229–241.
66. Merlano M, Vitale V, Rosso R: **Treatment of advance squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy.** *N Eng J Med* 1992, **327**:1115–1121.
67. Brizel DM, Leopold KA, Fisher SR: **A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck.** *Int J Radiat Oncol Biol Phys* 1994, **28**:213–220.

doi:10.1186/1472-6831-12-22

Cite this article as: Panghal et al.: Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols. *BMC Oral Health* 2012 **12**:22.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

